Azilsartan improves glycemic status and reduces kidney damage in zucker diabetic fatty rats

American Journal of Hypertension

Volumn 27, Issue 8, 2014, Pages 1087-1095

  Khan, Md Abdul Hye ^a   Neckár, Jan ^a,b   Haines, Jasmine ^a   Imig, John D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

Azilsartan medoxomil; Blood pressure; Hypertension; Inflammation; Kidney injury; Oxidative stress; Type 2 diabetes

Indexed keywords

AZILSARTAN MEDOXOMIL; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; AZILSARTAN; BENZIMIDAZOLE DERIVATIVE; GLUCOSE BLOOD LEVEL; OXADIAZOLE DERIVATIVE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEPRESSED BLOOD PRESSURE; DRUG EFFICACY; GENE MUTATION; GENETIC CODE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPERTENSION; IMMUNOPATHOLOGY; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY INJURY; KIDNEY PARENCHYMA; METABOLIC SYNDROME X; NEPHRINURIA; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHENOTYPE; PROTEINURIA; RAT; RENAL PROTECTION; TREATMENT DURATION; URINARY EXCRETION; URINARY TRACT DISEASE; ZUCKER DIABETIC FATTY RAT; ANIMAL; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; MALE; METABOLISM; PATHOLOGY; VASCULAR ENDOTHELIUM; ZUCKER RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; MALE; OXADIAZOLES; OXIDATIVE STRESS; RATS; RATS, ZUCKER;

EID: 84905824093     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu016     Document Type: Article

References (44)

1. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
3. Siwy J, Zoja C, Klein J, Benigni A, Mullen W, Mayer B, Mischak H, Jankowski J, Stevens R, Vlahou A, Kossida S, Perco P, Bahlmann FH. Evaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles. PLoS One 2012; 7: e51334.
4. Gray SP, Cooper ME. Diabetic nephropathy in 2010: alleviating the burden of diabetic nephropathy. Nat Rev Nephrol 2011; 7: 71-73.
5. Forcheron F, Basset A, Abdallah P, Del Carmine P, Gadot N, Beylot M. Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model-The Zucker diabetic rat. Cardiovasc Diabetol 2009; 8: 16.
6. Marchant K. Diabetes and chronic kidney disease: a complex combination. Brit J Nursing 2008; 17: 356-361.
7. Singh AK, Kari JA. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 2013; 22: 198-203.
8. Stewart JH, McCredie MRE, Williams SM, Jager KJ, Trpeski L, McDonald SP. Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, experimental diabetes research 11 in persons aged 20-64 years in Europe, Canada and the Asia-Pacific region, 1998-2002. Nephrology 2007; 12: 520-527.
9. Wakai K, Nakai S, Kikuchi K, Iseki K, Miwa N, Masakane I, Wada A, Shinzato T, Nagura Y, Akiba T. Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause. Nephrol Dial Transplant 2004; 19: 2044-2052.
10. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24: 11-25.
11. Komers R, Komersova K. Therapeutic potential of ACE inhibitors for the treatment of hypertension in type 2 diabetes. Expert Opin Investig Drugs 2000; 9: 2601-2617.
12. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001; 345: 861-869.
13. Viberti G, Wheeldon NM; Microalbuminuria Reduction With Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106: 672-678.
14. Purves RD. Optimal numerical integration methods for estimation of area-under-The-curve and area-under-The-moment-curve (AUMC). J Pharmacokinet Biopharm 1992; 20: 211-226.
15. Wakai K, Nakai S, Kikuchi K, Iseki K, Miwa N, Masakane I, Wada A, Shinzato T, Nagura Y, Akiba T. Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause. Nephrol Dial Transplant 2004; 19: 2044-2052.
16. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
17. Nakagawa T, Tanabe K, Croker BP, Johnson RJ, Grant MB, Kosugi T, Li Q. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol 2011; 7: 36-44.
18. Friedman EA, Friedman AL. Is there really good news about pandemic diabetic nephropathy? Nephrol Dial Transplant 2007; 22: 681-683.
19. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 2006; 6: 479-483.
20. Lehmann R, Schleicher ED, Lehmann R, Schleicher ED. Molecular mechanism of diabetic nephropathy. Clin Chim Acta 2000; 297: 135-144.
21. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001; 109: S424-S437.
22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
23. Moser M. Update on the management of hypertension: recent clinical trials and the JNC 7. J Clin Hypertens (Greenwich) 2004; 10: 4-13.
24. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med 2001; 345: 851-860.
25. Coimbra TM, Janssen U, Gröne HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000; 57: 167-182.
26. Gassler N, Elger M, Kränzlin B, Kriz W, Gretz N, Hähnel B, Hosser H, Hartmann I. Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat. Kidney Int 2001; 60: 106-116.
27. Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanabe T, Nomoto K, Nagata M. Podocyte injury promotes progressive nephropathy in Zucker diabetic fatty rats. Lab Invest 2002; 82: 25-35.
28. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006; 38: 64-80.
29. Uehara Y, Hirawa N, Kawabata Y, Numabe A, Gomi T, Ikeda T, Omata M. Angiotensin II subtype-1 receptor antagonists improve hemodynamic and renal changes without affecting glucose metabolisms in genetic rat model of non-insulin-dependent diabetes mellitus. Am J Hypertens 1999; 12: 21-27.
30. Mizuno M, Sada T, Kato M, Koike H. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 2002; 25: 271-278.
31. Janiak P, Bidouard JP, Cadrouvele C, Poirier B, Gouraud L, Grataloup Y, Pierre F, Bruneval P, O'Connor SE, Herbert JM. Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats. Eur J Pharmacol 2006; 534: 271-279.
32. Yamada S. Pleiotropic effects of ARB in metabolic syndrome. Curr Vasc Pharmacol 2011; 9: 158-161.
33. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgammamodulating activity. Hypertension 2004; 43: 993-1002.
34. Taguchi I, Toyoda S, Takano K, Arikawa T, Kikuchi M, Ogawa M, Abe S, Node K, Inoue T. Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension. Hypertens Res 2013; 36: 608-613.
35. Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007; 20: 579-586.
36. Kurtz TW, Kajiya T. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag 2012; 8: 133-143.
37. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18: 1880-1888.
38. Kinoshita Y, Kondo S, Urushihara M, Suga K, Matsuura S, Takamatsu M, Shimizu M, Nishiyama A, Kawachi H, Kagami S. Angiotensin II type I receptor blockade suppresses glomerular renin-angiotensin system activation, oxidative stress, and progressive glomerular injury in rat anti-glomerular basement membrane glomerulonephritis. Transl Res 2011; 158: 235-248.
39. Toblli JE, Cao G, Giani JF, Muñoz MC, Angerosa M, Dominici FP. Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats. J Hypertens 2011; 29: 1613-1623.
40. Jiao B, Wang YS, Cheng YN, Gao JJ, Zhang QZ. Valsartan attenuated oxidative stress, decreased MCP-1 and TGF-β1 expression in glomerular mesangial and epithelial cells induced by high-glucose levels. Biosci Trends 2011; 5: 173-181.
41. Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, Pinto R, Garrido P, Sereno J, Fernandes R, Santos P, Velada I, Melo A, Nunes S, Teixeira F, Reis F. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010; 2010: 592760.
42. Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L, Esposito K, Giugliano D. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111: 2518-2524.
43. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107.
44. Shimamura M, Nakagami H, Shimosato T, Moritani T, Nakagami F, Osako MK, Miyake T, Koriyama H, Shimizu H, Morishita R. Irbesartan improves endothelial dysfunction, abnormal lipid profile, proteinuria and liver dysfunction in Zucker diabetic fatty rats independent of glucose and insulin levels. Exp Ther Med 2011; 2: 957-961.